The shelf is now live, so PoC Capital can sell shares at any time. Monitor for a Form 4 filing indicating the start of the resale, which would signal near-term selling pressure. The $1,000,000 funding commitment provides a modest cash buffer for clinical trial costs.
Price Chart
Executive Summary
The SEC declared effective MAIA Biotechnology's S-3 shelf registration (File No. 333-299148) on October 6, 2026. This allows the company to sell up to 751,879 shares of common stock held by PoC Capital LLC, received under a Clinical Trial Funding Agreement. The effectiveness introduces potential dilution overhang of ~1.2% of shares outstanding, but the company receives no proceeds from the resale.
Key Facts
- Effectiveness date: October 6, 2026
- Shelf registration for 751,879 shares of common stock
- Shares registered for resale by PoC Capital LLC
- Company receives no proceeds from the resale
- Shares were issued under a Clinical Trial Funding Agreement dated August 29, 2026
- PoC Capital agreed to provide $1,000,000 in funding for clinical trial expenses
Financial Impact
Potential dilution of approximately 1.2% of shares outstanding; company receives no proceeds from the resale but secured $1,000,000 in clinical trial funding from PoC Capital.
Risk Factors
- Resale by PoC Capital could create downward pressure on the stock price
- No proceeds to the company from the resale — dilution without capital benefit
- Clinical-stage biotech with no approved products; cash runway dependent on continued funding
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-003161 |
| Document: 9999999995-26-003161-index.html | 9999999995-26-003161 |
| Document: 9999999995-26-003161.txt | 9999999995-26-003161 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 20d ago | EFFECT | $1.18 | awaiting T+60 | — | $1.13 (+4.24%) |
Oct 6, 2026 21d ago | 8-K | $1.19 | awaiting T+60 | — | $1.13 (−5.04%) |
Sep 25, 2026 4w ago | S-3 | $1.18 | awaiting T+60 | — | $1.13 (+4.24%) |
Sep 16, 2026 5w ago | Press Release | $1.40 | awaiting T+60 | — | $1.13 (−19.29%) |
Sep 15, 2026 6w ago | Press Release | $1.34 | awaiting T+60 | — | $1.13 (−15.67%) |
Sep 15, 2026 6w ago | Insider Cluster | $1.34 | awaiting T+60 | — | $1.13 (−15.67%) |
Jun 3, 2026 20w ago | Press Release | $1.43 $1.38 | ▼ −3.50% | ▼ −6.00% | $1.13 (−20.98%) |
Jun 2, 2026 21w ago | Insider Cluster | $1.35 $1.39 | ▲ +2.96% | ▲ +1.85% | $1.13 (−16.30%) |
May 19, 2026 23w ago | DEFA14A | $1.23 $1.34 | ▲ +8.94% | ▲ +2.65% | $1.13 (−8.13%) |
May 14, 2026 23w ago | 8-K | $1.26 $1.38 | ▲ +9.52% | ▲ +5.01% | $1.13 (−10.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers